Company: NIVFW
Filing Date: 2025-06-03
Form Type: 424B3
Source: 0001213900-25-050825
Chunk: 202

Company: NewGenIvf Group Ltd
Filing Date: 2025-06-03
Form: 424B3
Chunk 202
---
’s ordinary
shares are stated at no par value. The difference between the consideration received, net of issuance cost, is recorded in additional
paid-in capital.

On January 21, 2025, the
Board of Directors of the Company approved a reverse stock split of all of the Company’s issued and unissued shares, including the
Class A ordinary shares with no par value (the “Class A Ordinary Shares”), Class B ordinary shares with no par value and preferred
shares with no par value, at an exchange ratio of one (1) share for twenty (20) shares (the “Reverse Stock Split”). Upon the
opening of the market on February 11, 2025, the Company’s Class A Ordinary Shares will begin trading on the Nasdaq Global Market
(“Nasdaq”) on a post-Reverse Stock Split basis.

On April 15, 2025, the
Board of Directors of the Company approved a reverse stock split of all of the Company’s issued and unissued shares, including
the Class A ordinary shares with no par value (the “Class A Ordinary Shares”), Class B ordinary shares with no par value
and preferred shares with no par value, at an exchange ratio of one (1) share for ten (10) shares (the “Reverse Stock Split”).
Upon the opening of the market on May 5, 2025, the Company’s Class A Ordinary Shares began trading on the Nasdaq Capital Market
(“Nasdaq”) on a post-Reverse Stock Split basis.

In accordance with ASC 505,
the reverse stock split is to be accounted for retrospectively.

The Company adopted ASC Topic 606,
Revenue from Contracts with Customers, and all subsequent ASUs that modified ASC 606 on April 1, 2017 using the full retrospective
method which requires the Company to present the financial statements for all periods as if Topic 606 had been applied to all prior
periods. The Company derives revenue principally from provision of In vitro fertilization (“IVF”) treatment and surrogacy
and ancillary caring services. Revenue from contracts with customers is recognized using the following five steps:

| (1) | identify its contracts with customers;                                                                                                                                                                                                                  |
| (2) | identify its performance obligations under those contracts;                                                                                                                                                                                             |
| (3) | determine the transaction prices of those contracts;                                                                                                                                                                                                    |
| (4) | allocate the transaction prices to its performance obligations in those contracts; and                                                                                                                                                                  |
| (5) | recognize revenue